Navigation Links
Reaction to Avandia Warnings Stronger Among Internists Than,Endocrinologists, According to Study by GfK Market Measures

EAST HANOVER, N.J.--(BUSINESS WIRE)--Jul 11, 2007 - Since the May 2007 release of a New England Journal of Medicine (NEJM) report that Avandia users are 43 percent more likely to suffer a heart attack and 67 percent more likely to die of cardiovascular causes than non-users of Avandia, it is no surprise that physicians intend to switch many type 2 diabetes patients from Avandia to therapies believed to pose less risk. Research from GfK Market Measures' Event Flash, Physicians' Reactions to NEJM's Results on Avandia's Increased CV Risk, suggests, however, a greater negative response by internists than endocrinologists.

The GfK Market Measures study showed universal awareness of the NEJM report, though not all physicians recalled the exact percentages. The internists, however, demonstrated the strongest negative impact to the findings signaling they will "switch more than half their patients currently on Avandia to another therapy," according to Anna Marie Napolitano, Vice President and Leader of GfK Market Measures' Cardiology Practice. "This sharply contrasts with general/family practitioners and endocrinologists who expect to switch less than half of their patients."

Forty percent of internists also indicated a high likelihood they will take all of their Avandia, Avandamet and Avandaryl patients off each respective drug, even though the FDA has not required it, in contrast to a smaller percentage of endocrinologists. Internists are also more likely than the endocrinologists to indicate a reluctance to prescribe any product containing Avandia.

To a lesser degree, the news of Avandia's effect on cardiovascular risk may have negatively impacted physicians' perceptions of ACTOS. One-third of internists and about one-quarter of general/family practitioners and endocrinologists report they are reluctant to prescribe ACTOS or any other product containing ACTOS (i.e., ACTOplus met).

The GfK Market
'"/>




Page: 1 2 3

Related medicine technology :

1. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
2. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
3. FDA Issues Safety Alert on Avandia
4. FDA Proposes New Warnings About Suicidal Thinking, Behavior in Young Adults Who Take Antidepressant Medications
5. Data Show FluMist May Reduce Seasonal Influenza Burden Among Children in School, Daycare Settings
6. Exforge Helps Vast Majority of Patients Effectively Control Their Blood Pressure After Failing on Other Medicines, According to New Clinical Data
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
9. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
10. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:12/24/2014)... TIJUANA, Mexico , Dec. 24, 2014 /PRNewswire/ ... treatment of its first patient in its study ... to the American Stroke Association, ischemic strokes account ... continues to enroll qualified patients in the study, ... Intravenous Administration of Allogeneic Mesenchymal Stem Cells and ...
(Date:12/24/2014)... PRINCETON, N.J. , Dec. 24, 2014 /PRNewswire/ ... Company), a late-stage biopharmaceutical company developing products that ... inflammation, oncology and biodefense, announced today that on ... registered public offering. The Company raised ... offering and intends to use the net proceeds ...
(Date:12/24/2014)... and LONDON , December 24, ... industry are expected to grow at an average rate ... of value and volume. Hip, knee and spine surgeries ... while in emerging economies they have a lower penetration. ... challenging the use of composites. Non-metallic orthopedic devices have ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
... Pharmaceuticals, Inc. (NYSE: WPI ) today ... Watson Laboratories, Inc. -- Florida, (collectively "Watson") filed ... Food and Drug Administration (FDA) seeking approval to ... 20, 30, 40, 60 and 80 mg strengths. ...
... Science (Tianjin) Co. Ltd, a leading research-based contract manufacturer of ... in the U.S. and China, is pleased to announce the ... Quality Assurance as of March 1, 2011. ... in the pharmaceutical industry (early and late stage), in quality ...
Cached Medicine Technology:Watson Confirms OxyContin® Patent Challenge 2Watson Confirms OxyContin® Patent Challenge 3Mr. Robert Andrews Joins Asymchem Life Science (Tianjin) Co. Ltd. as Vice President of Quality Assurance 2
(Date:12/25/2014)... December 26, 2014 The ... combines beauty, strength and durability. Today, the business ... which is valid until Jan. 30, 2015. , ... of traditional hardwood. BambooFlooringChina.com is a well-known brand ... consumers worldwide to find a reliable bamboo flooring ...
(Date:12/25/2014)... iFitDress.com, the popular online supplier of wedding dresses and special ... black one-shoulder cocktail dresses . In addition, all these ... discounted prices, up to 70% off. , The ... only. You know, we have thousands of frequent callers in ... items can visit our website for more details. The current ...
(Date:12/25/2014)... 25, 2014 Helen Harris’ RP (Retinitis ... Hills, California after an 8 year battle with breast ... Eve evening in her home in Woodland Hills California ... cancer. , As the founder and ... she pioneered and championed many of today's greatest breakthroughs ...
(Date:12/25/2014)... 25, 2014 (HealthDay News) -- Overeating is common during the ... in moderation, an expert says. "Don,t arrive at a ... if you know you,ll be attending a party, but deprivation ... lead dietitian at Northern Westchester Hospital in Mount Kisco, N.Y., ... eat healthy during the day and even to have a ...
(Date:12/25/2014)... December 25, 2014 “ SmileStix ” was ... features the latest and coolest mobile applications on the iOS, ... and host of NewsWatch, conducted the app review and shared ... create personal stickers. , The old saying goes, “A picture ... of words that can describe a single image, because each ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... for bowel cancer at Queen,s University Belfast has received ... Dr Sandra Van Schaeybroeck, whose research aims to identify ... a prestigious 688,000 Cancer Research UK Clinical Scientist Fellowship. ... four fellowships awarded to UK clinical investigators, renews Dr ...
... ,Surgeons aged 35 to 50 provide the safest care for ... about ongoing training and motivation of surgeons during their careers, ... France. They analyzed data from 3,574 thyroidectomies (removal of ... over a one-year period. The average age of the surgeons ...
... , TUESDAY, Jan. 10 (HealthDay News) -- Children with autism ... bacteria seen in kids who do not have the disorder, ... 10 in the online journal mBio , researchers from ... New York City suggested that this finding could help explain ...
... patients improved between 2003 and 2008, according to a ... Outcomes , an American Heart Association journal. The study ... of care, and that differences in care between the ... because little is known about the treatment and outcomes ...
... By Serena Gordon HealthDay Reporter , TUESDAY, Jan. ... new research suggests those costs may extend far beyond the ... study authors found that young people with diabetes were more ... lifetime, could expect to earn about $160,000 less than those ...
... that older Americans with cirrhosis have significantly worse health ... this potentially deadly disease. In fact, findings now published ... American Association for the Study of Liver Diseases, show ... of informal caregiving and contribute added strain on the ...
Cached Medicine News:Health News:Groundbreaking cancer research receives massive funding boost 2Health News:Surgeons in Mid-Career Have Fewest Complications: Study 2Health News:Autism Gastro Problems May Be Linked to Gut Bacteria 2Health News:Asian-Americans getting better heart attack care 2Health News:Diabetes Takes a Toll on Lifetime Earnings: Study 2Health News:Diabetes Takes a Toll on Lifetime Earnings: Study 3Health News:Diabetes Takes a Toll on Lifetime Earnings: Study 4Health News:High rates of disability and health care use for older americans with cirrhosis 2
The Stryker CBCII Blood Conservation System provides a safe, simple and economic disposable system for blood reinfusion....
The Rapid Programmer 3.0 is the smallest and lightest-weight clinician programming platform in the industry. It enables clinicians to quickly and efficiently test patients intraoperatively and to cre...
... systems are intended to provide ventricular antitachycardia ... of life-threatening ventricular arrhythmias. In patients indicated ... systems are also intended:, to provide ... to severe heart failure (NYHA Functional Class ...
Used for implantation to reinforce soft tissue where weakness exists. Indications for use include repair of a hernia or body wall defect. Supplied sterile in peel-open packages. Intended for one-time...
Medicine Products: